305 related articles for article (PubMed ID: 21234526)
1. Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results.
Semrau S; Waldfahrer F; Lell M; Linke R; Klautke G; Kuwert T; Uder M; Iro H; Fietkau R
Strahlenther Onkol; 2011 Jan; 187(1):15-22. PubMed ID: 21234526
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E
J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517
[TBL] [Abstract][Full Text] [Related]
3. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.
Shirinian MH; Weber RS; Lippman SM; Dimery IW; Earley CL; Garden AS; Michaelson J; Morrison WH; Kramer A; Byers R
Head Neck; 1994; 16(1):39-44. PubMed ID: 7510276
[TBL] [Abstract][Full Text] [Related]
4. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
5. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
Cmelak AJ; Murphy BA; Burkey B; Douglas S; Shyr Y; Netterville J
Head Neck; 2007 Apr; 29(4):315-24. PubMed ID: 17252600
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
[TBL] [Abstract][Full Text] [Related]
7. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).
Dietz A; Rudat V; Dreyhaupt J; Pritsch M; Hoppe F; Hagen R; Pfreundner L; Schröder U; Eckel H; Hess M; Schröder M; Schneider P; Jens B; Zenner HP; Werner JA; Engenhardt-Cabillic R; Vanselow B; Plinkert P; Niewald M; Kuhnt T; Budach W; Flentje M
Eur Arch Otorhinolaryngol; 2009 Aug; 266(8):1291-300. PubMed ID: 18972123
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation.
Pfreundner L; Hoppe F; Willner J; Preisler V; Bratengeier K; Hagen R; Helms J; Flentje M
Radiother Oncol; 2003 Aug; 68(2):163-70. PubMed ID: 12972311
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Miah AB; Bhide SA; Guerrero-Urbano MT; Clark C; Bidmead AM; St Rose S; Barbachano Y; A'hern R; Tanay M; Hickey J; Nicol R; Newbold KL; Harrington KJ; Nutting CM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):539-47. PubMed ID: 21236602
[TBL] [Abstract][Full Text] [Related]
12. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
[TBL] [Abstract][Full Text] [Related]
14. Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx.
Semrau S; Schmidt D; Lell M; Waldfahrer F; Lettmaier S; Kuwert T; Iro H; Fietkau R
Oral Oncol; 2013 May; 49(5):454-60. PubMed ID: 23321550
[TBL] [Abstract][Full Text] [Related]
15. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
16. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis.
Balermpas P; Bauer C; Fraunholz I; Ottinger A; Wagenblast J; Stöver T; Seitz O; Fokas E; Rödel C; Weiss C
Strahlenther Onkol; 2014 Mar; 190(3):256-62. PubMed ID: 24413895
[TBL] [Abstract][Full Text] [Related]
17. Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma.
Kutter J; Ozsahin M; Monnier P; Stupp R
Eur Arch Otorhinolaryngol; 2005 Jan; 262(1):1-7. PubMed ID: 15004704
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Nishimura G; Tsukuda M; Horiuchi C; Satake K; Yoshida T; Nagao J; Kawakami M; Kondo N; Arai Y; Taguchi T; Matsuda H; Mikami Y
Auris Nasus Larynx; 2007 Dec; 34(4):499-504. PubMed ID: 17604583
[TBL] [Abstract][Full Text] [Related]
19. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Guadagnolo BA; Haddad RI; Posner MR; Weeks L; Wirth LJ; Norris CM; Sullivan CA; Goguen L; Busse PM; Tishler R
Am J Clin Oncol; 2005 Aug; 28(4):371-8. PubMed ID: 16062079
[TBL] [Abstract][Full Text] [Related]
20. Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers.
Imai S; Kajihara Y; Munemori O; Kamei T; Mori T; Handa T; Akisada K; Orita Y
Eur J Radiol; 1995 Dec; 21(2):94-9. PubMed ID: 8850500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
